25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Among the major neurodegenerative disorders (NDDs), Alzheimer’s disease (AD) and Parkinson’s disease (PD), are a huge socioeconomic burden. Over many centuries, people have sought a cure for NDDs from the natural herbals. Many medicinal plants and their secondary metabolites are reported with the ability to alleviate the symptoms of NDDs. The major mechanisms identified, through which phytochemicals exert their neuroprotective effects and potential maintenance of neurological health in ageing, include antioxidant, anti-inflammatory, antithrombotic, antiapoptotic, acetylcholinesterase and monoamine oxidase inhibition and neurotrophic activities. This article reviews the mechanisms of action of some of the major herbal products with potential in the treatment of NDDs according to their molecular targets, as well as their regional sources (Asia, America and Africa). A number of studies demonstrated the beneficial properties of plant extracts or their bioactive compounds against NDDs. Herbal products may potentially offer new treatment options for patients with NDDs, which is a cheaper and culturally suitable alternative to conventional therapies for millions of people in the world with age-related NDDs.

          Related collections

          Most cited references97

          • Record: found
          • Abstract: found
          • Article: not found

          Pathology of Neurodegenerative Diseases.

          Neurodegenerative disorders are characterized by progressive loss of selectively vulnerable populations of neurons, which contrasts with select static neuronal loss because of metabolic or toxic disorders. Neurodegenerative diseases can be classified according to primary clinical features (e.g., dementia, parkinsonism, or motor neuron disease), anatomic distribution of neurodegeneration (e.g., frontotemporal degenerations, extrapyramidal disorders, or spinocerebellar degenerations), or principal molecular abnormality. The most common neurodegenerative disorders are amyloidoses, tauopathies, α-synucleinopathies, and TDP-43 proteinopathies. The protein abnormalities in these disorders have abnormal conformational properties. Growing experimental evidence suggests that abnormal protein conformers may spread from cell to cell along anatomically connected pathways, which may in part explain the specific anatomical patterns observed at autopsy. In this review, we detail the human pathology of select neurodegenerative disorders, focusing on their main protein aggregates.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease

            Parkinson's disease (PD) is a complex, chronic and progressive neurodegenerative disease. While the etiology of PD is likely multifactorial, the protein α-synuclein is a central component to the pathogenesis of the disease. However, the mechanism by which α-synuclein causes toxicity and contributes to neuronal death remains unclear. Mitochondrial dysfunction is also widely considered to play a major role in the underlying mechanisms contributing to neurodegeneration in PD. This review discusses evidence for the neuropathological role for α-synuclein in the dysfunction of dopamine neurons in PD. We also discuss insights into the structure, localization, and cellular roles for α-synuclein that may influence its aggregation properties, ultimately impacting its pathogenicity, role in lysosomal dysfunction and activation of the neuroimmune response. We further highlight recent evidence linking α-synuclein and mitochondrial dysfunction in neurodegeneration. Identifying the underlying mechanisms responsible for this bi-directional relationship between α-synuclein and mitochondrial dysfunction may provide new insights into the pathophysiology of PD.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Natural products in cancer chemotherapy: past, present and future.

              John Mann (2002)
              Natural products have been the mainstay of cancer chemotherapy for the past 30 years. However, the quickening pace of (aberrant) gene identification, and the new technologies of combinatorial chemistry and high-throughput screening, should provide access to a wide range of new, totally synthetic drugs. Will these new approaches sound the death knell for therapies based on natural products? In reality, natural products are likely to provide many of the lead structures, and these will be used as templates for the construction of novel compounds with enhanced biological properties.
                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                08 April 2020
                April 2020
                : 9
                : 4
                : 1061
                Affiliations
                [1 ]Department of Medical Parasitology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman 7616913555, Iran; mehdi_sharifirad@ 123456yahoo.com
                [2 ]School of Health and Biomedical Sciences, RMIT University, Bundoora, PO Box 71, VIC 3083, Australia; chintha.lankatillake@ 123456rmit.edu.au
                [3 ]Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; daoana00@ 123456gmail.com
                [4 ]Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam; f.mahomoodally@ 123456uom.ac.mu or
                [5 ]Department of Health Sciences, Faculty of Science, University of Mauritius, Réduit 80837, Mauritius; devinalobine@ 123456gmail.com
                [6 ]Department of Biosciences, Durham University, Durham DH1 3LE, UK; paul.chazot@ 123456durham.ac.uk
                [7 ]Graduate Program of Biomolecular Sciences, Institute of Natural and Applied Sciences, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey; begum@ 123456stu.comu.edu.tr
                [8 ]Department of Molecular Biology and Genetics, Faculty of Arts and Science, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey; tumertb@ 123456gmail.com
                [9 ]Pulmonology Department, Hospital Garcia de Orta, EPE Almada, 2801-951 Lisboa, Portugal; catarina_icbas@ 123456hotmail.com
                [10 ]Department of Pharmaceutical Technology, Avicenna Tajik State Medical University, Rudaki 139, Dushanbe 734003, Tajikistan; shfarukh@ 123456mail.ru
                [11 ]Department of Nutrition and Dietetics, Faculty of Pharmacy, University of Concepcion, Concepcion 4070386, Chile; martorellpons@ 123456gmail.com
                [12 ]Universidad de Concepción, Unidad de Desarrollo Tecnológico, UDT, Concepcion 4070386, Chile
                [13 ]Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
                [14 ]Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal
                [15 ]Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China
                [16 ]Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
                [17 ]Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1991953381, Iran
                Author notes
                [†]

                Equal first author, these authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-0129-3178
                https://orcid.org/0000-0003-3962-8666
                https://orcid.org/0000-0002-1740-4867
                https://orcid.org/0000-0003-0378-8887
                https://orcid.org/0000-0003-3183-7623
                https://orcid.org/0000-0002-5934-5201
                https://orcid.org/0000-0003-4174-4586
                https://orcid.org/0000-0002-1523-9116
                https://orcid.org/0000-0002-7301-8151
                Article
                jcm-09-01061
                10.3390/jcm9041061
                7231062
                32276438
                150bcd04-7781-4506-b99a-990d42eb331e
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 24 February 2020
                : 03 April 2020
                Categories
                Review

                neurodegenerative disorders,alzheimer’s disease,dementias,parkinson’s disease,natural compounds,plants secondary metabolites,pharmacological activities

                Comments

                Comment on this article